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Background
Several non-steroidal anti-inflammatory drugs (NSAIDs)
have been reported to be effective in the management of
acute migraine: among them, Diclofenac (DF) is one of
the most effective compounds when administered either
orally or intramuscularly. DF is a potent NSAID that
has been in clinical use for many years, particularly
effective for the treatment of inflammatory, degenerative
and rheumatic diseases, soft-tissue rheumatism and
non-rheumatic painful and inflammatory conditions
(post-traumatic, postoperative pain and migraine head-
ache). Among the different forms of administration a
novel injectable DF formulation (dissolved in a volume
of 1 ml) containing an enhancer of solubility, based
idrissipropilbetacyclodextrin (HPbCD) has been recently
introduced in Italy. This formulation allows the use into
subcutaneous (s.c.) tissue and is characterized by a bioa-
vailability and a safety profile comparable both to the
i.m. DF formulation at a dose of 75 mg/3ml (on the
market for parenteral treatment) and os DF formulation
at a dose of 50 mg. Up to now no study has been per-
formed on DF to assess the point of view of patients in
relation to the ease of use of a route of administration
with respect to another: this contribution is the first to
do so.
Patients and methods
Setting Area: UO Terapia del Dolore-Centro Cefalee
SISC UCSC/CIC. Patients (53: 35 F/18 M) with an
established migraine diagnosis (according to the ICHD-
III criteria), a disease duration of at least 1 year and two
to six migraine attacks per month over the previous 3
months, using DF potassium (50 mg) oral solution for
the acute (moderate) treatment, were switched to subcu-
taneous injection of DFHPbCD (25 mg). At the follow-
ing visit, patients were required to compare, in addition
to the parameters of speed of onset of action, efficacy
and tolerability, also the ease of use of the two routes of
administration.
Results
The results are reported in Table 1.
Conclusions
Patients consistently expressed a clear preference for DF
HPbCD (25 mg s.c) over DF potassium (50 mg os).
Since patients are treated on an individual basis, the
more important question is not only which drug is best
in relation to the other but, whether the chosen one has
a route of administration that better fits the outcome
desired by the patient, encompassing also ease of use
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and feelings of well-being on an individual basis and by
the healthcare provider. Compared with the DF potas-
sium (50 mg os) reference therapy, DF HPbCD (25 mg
s.c) presents interesting advantages in terms of ease of
use, onset of analgesic effect and tolerability profile.
Further studies are needed to confirm the data obtained
from this preliminary investigation.
Written informed consent to publish was obtained
from the patient(s).
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Table 1
Patient’s (53: 35 F, 18 M) subjective judgement (point of view) about Diclofenac
HPbCD 25 mg s.c. vs Diclofenac potassium 50 mg os
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